In a significant move to support veterinary professionals, the American Veterinary Medical Association (AVMA) has released an updated report entitled “Cannabis in Veterinary Medicine.” This comprehensive document aims to provide veterinarians and pet owners with a deeper understanding of the laws, scientific research, and potential implications surrounding the use of cannabis-derived products in companion animals.
Published in April, the report touches on several key areas, offering a detailed overview of the current cannabis landscape. It begins by exploring the historical perspective on cannabis in the US, setting the stage for the subsequent examination of the pharmacology of cannabis and the endocannabinoid system.
One primary focus of the report is the clinical research investigating the therapeutic potential and pharmacokinetics of cannabis-derived products, particularly cannabidiol (CBD), in dogs and cats. The AVMA team has meticulously reviewed preclinical studies that provided valuable insights into the effects of CBD-rich hemp products on companion animals. This includes data on pharmacokinetic properties and potential adverse effects.
“The report primarily focuses on dogs and cats due to the limited availability of well-controlled clinical studies for other species,” explained Dr. Dharati Szymanski, an assistant director in AVMA’s Division of Animal and Public Health, who oversaw the update of the report.
In addition to the scientific findings, the report talks about the complex regulations surrounding the use of cannabis-derived products in animals. This section provides an updated overview of the state and federal regulations that veterinary professionals must comply with when considering the application of these products.
Dr. Szymanski emphasized the importance of this regulatory update, stating, “AVMA continues to work to support veterinarians in maintaining a current understanding of the many aspects of cannabis-derived products in veterinary medicine.”
The report also covers other critical areas, such as analytical testing and quality control in the cannabis industry, as well as the potential risks of cannabis toxicosis in companion animals.
“This latest iteration of the report is a valuable resource for veterinary professionals,” Dr. Szymanski added. “As the AVMA has been receiving a growing number of inquiries about the efficacy, safety, and legality of cannabis-derived products, this updated report aims to provide the necessary information [for veterinarians] to make informed decisions and better serve their patients and clients.”
By offering a comprehensive and up-to-date perspective on the complex and rapidly evolving field of cannabis in veterinary medicine, the AVMA report is a crucial tool for veterinary professionals.
